|Bid||50.56 x 1000|
|Ask||50.57 x 900|
|Day's Range||49.91 - 50.83|
|52 Week Range||38.48 - 61.71|
|Beta (5Y Monthly)||0.62|
|PE Ratio (TTM)||14.47|
|Forward Dividend & Yield||1.60 (2.93%)|
|Ex-Dividend Date||Jan 27, 2022|
|1y Target Est||N/A|
NEW YORK & NEW HAVEN, CONN., May 10, 2022--Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.
BASEL, Switzerland, and NEW YORK, May 06, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis. The FDA requires extended time to review additional information the Ag
NEW YORK, May 03, 2022--Pfizer Inc. (NYSE: PFE) reported strong financial results for first-quarter 2022 and updated certain components of 2022 financial guidance(4). Pfizer reaffirmed its previous 2022 revenue guidance, including its guidance for Comirnaty(1), the Pfizer-BioNTech SE (BioNTech) COVID-19 vaccine, and for Paxlovid, its oral COVID-19 treatment, despite unfavorable impacts from foreign exchange.